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Graphene oxide (GO) has many exciting advantages such as easy preparation, low toxicity, good solubility
and stability in aqueous solution. However, GO itself has a low near-infrared (NIR) absorption, and thus is
not suitable for photothermal therapy and photoacoustic imaging. To overcome this limitation, a novel
dye-enhanced GO is prepared utilizing the p–p stacking interactions between GO and indocyanine
green (ICG). The ICG–GO complex has a high optical absorbance in the NIR region and exhibits excellent
photothermal properties under NIR irradiation. In order to improve the cancer-targeting activity, GO
was modified with folic acid (FA). In vitro experiments showed that the ICG–GO–FA nanocomposite
could be used for targeted photothermal cancer cell destruction. Moreover, the application of the
ICG–GO–FA nanocomposite for photoacoustic imaging was also demonstrated.1. Introduction
Cancer is a major public health problem in the United States
and many other parts of the world. A total of 1 660 290 new
cancer cases and 580 350 cancer deaths are projected to occur in
the United States in 2013.1 It is therefore necessary to develop
efficient methods for the treatment of cancer. Photothermal
therapy (PTT) is a promising treatment modality for cancers and
other malignant diseases in a minimally invasive manner. In
this treatment, NIR-absorbing photothermal agents are rst
delivered to targeted cells or tissues and then irradiated with a
NIR laser which can penetrate relatively deep into tissues
without damaging normal biological tissues. The absorbed light
is then converted to heat and transferred to the cell environ-
ment, generating localized hyperthermia and destroying cancer
cells. Recently, there has been an explosion of interest in the
development of nanomaterials for photothermal therapy due to
their improved NIR-absorption, photo-stability or photothermal
conversion efficiency. Examples of these materials include
organic nanoparticles,2–5 gold nanostructures,6–9 copper chal-
cogenide semiconductors,10,11 Pd nanosheets12 as well as carbon
nanotubes.13,14nology for Food Safety of the MOE, Fujian
Detection Technology for Food Safety,
ring, Fuzhou University, Fuzhou 350108,
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62–5767Graphene, a single layer of carbon atoms, has attracted great
attention recently.15 Until now, several methods have been
successfully established for the synthesis of graphene and its
derivatives. In the biomedical area,16–18 such as biosensing19–22
and drug delivery,23,24 the most commonly used derivatives of
graphene are graphene oxide (GO) and reduced graphene oxide
(RGO), due to their biocompatibility and easy synthesis at a
large scale and low cost. GO can be easily prepared from native
graphite akes according to the modied Hummers' method.25
Aer chemical reduction, GO can be transformed into RGO.
RGO has high NIR absorption and is reported to be a potential
photothermal agent for treatment of diseases, such as
cancer,26–29 Alzheimer's disease30 and bacterial infection.31,32
Compared with RGO, GO offers several advantages. First, GO is
practically non-toxic at certain concentration levels.33,34 In
contrast, the surface of RGO is highly hydrophobic, and thus it
is considered more toxic than the unreduced GO.35–37 Second,
GO contains hydrophilic functional groups that enable chem-
ical functionalization and water-solubility. Third, GO is easier to
degrade than RGO.38 The recent ndings on the possible
biodegradability of GO are another positive factor for GO to be
used in vivo.39 However, the NIR absorption of GO is much lower
than that of RGO, and thus GO itself is not suitable for photo-
thermal therapy.
Imaging techniques, based on targeted contrast agents are
also very important for earlier detection of tumors, under-
standing the distribution of photoabsorbers in tumors and
other organs, as well as assessing the therapeutic efficacy and
monitoring the post-treatment tumor behaviors.40 Photo-
acoustic tomography (PAT) is a novel hybrid imaging modality
that is based on the detection of acoustic waves generated by
absorption of pulsed light by tissue chromophores or targetedThis journal is ª The Royal Society of Chemistry 2013













































View Article Onlinecontrast agents. PAT has high contrast and good spatial reso-
lution. In addition, due to the intrinsic character of the
employed NIR light and generated ultrasonic signal, PAT is
believed to offer more accuracy than other imaging modalities
for guiding PTT.
Indocyanine green (ICG) is a Federal Drug Administration
approved agent for clinical NIR uorescence imaging.41 Because
of its intrinsic strong NIR absorption, ICG has also been used to
selectively increase the photothermal destructions in the target
tumors.42 However, most of the light-absorbing dyes including
ICG have some limitations, such as concentration-dependent
aggregation, poor photo-stability, non-specic binding to
proteins, lack of target specicity and short half-life in the
circulation.43 There are some reports on the improvement of the
stability of ICG.44,45 Encouraged by the good solubility of GO and
strong NIR absorption ability of ICG, we predicted that by the
combination of GO with ICG, a new ICG–GO complex can be
formed and used as a promising material for clinical diagnosis
and therapy of cancer.
Herein, we proved that the ICG–GO complex can be used as a
novel NIR-absorbing agent for photothermal therapy and a
good contrast agent for photoacoustic imaging. ICG–GO was
prepared by simply mixing GO with ICG. It was found that the
obtained ICG–GO possessed good photostability and an excel-
lent photothermal property. In order to improve the cancer-
targeting activity, ICG–GO was modied with folic acid (FA)
which targeted a variety of tumor cells over-expressing the folate
receptor (FR). In vitro experiments showed that ICG–GO–FA was
very biocompatible and exhibited non-cytotoxicity without NIR
irradiation. In contrast, in the presence of NIR irradiation,
ICG–GO–FA can be used for targeted photothermal ablation of
cancer cells. Photoacoustic imaging using ICG–GO was also
performed. Our results showed that ICG–GO could also be used
as a good photoacoustic contrast agent.2. Materials and methods
2.1. Materials and apparatus
Graphite powder (analytical grade) was purchased from
Sinopharm Chemical Reagent Co. Ltd (China). 3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 1-ethyl-3-
(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC),
N-hydroxysulfosuccinimide (NHS), ICG and FA were purchased
from Sigma-Aldrich. All the other chemicals were of analytical
grade and were used as received.
UV-vis absorption spectra were recorded using a SH-1000
Lab microplate reader (Corona Electric, Hitachinaka, Japan) at
room temperature. Atomic force microscopy (AFM) measure-
ment was performed with a Multimode 3D atomic force
microscope (Bruker Nano Inc., USA). A semiconductor laser unit
(KS3-11312-110, BWT, Beijing Kaipulin Co. Ltd, China) was
used for photothermal irradiation.2.2. Preparation of ICG–GO
GO was synthesized from graphite powder by a modied
Hummers method.25 Then, the solution of GO was centrifugedThis journal is ª The Royal Society of Chemistry 2013at 10 000 rpm for 10 min to remove any large size GO sheets.
The supernatant was collected. ICG (5 mg mL1) was dissolved
in DMSO rst and then added to GO water solutions (the nal
concentration of both GO and ICG is 0.5 mg mL1). Then the
solution was agitated overnight in the dark at 4 C. Unbound
ICG molecules were removed from the solution by ltration
through 10 kDa centrifuge lters (Millipore) and washed for 6–8
times.2.3. Preparation of RGO
To prepare RGO, hydrazine hydrate (100 mL) was added to the
GO solution (10 mL) at a concentration of 1 mg mL1 and
heated in an oil bath at 95 C under stirring for 30 min. The GO
solution changed color from yellow to black during the reduc-
tion step, indicating increased light absorption in the visible
and NIR region. The obtained RGO was characterized by Raman
spectroscopy on a Renishaw inVia Raman microspectrometer at
room temperature.2.4. Synthesis of NH2–PEG2000–FA
FA was conjugated with NH2–PEG2000–NH2 via EDC/NHS
chemistry. Typically, FA (0.01 mmol), EDC (0.05 mmol), and
NHS (0.03 mmol) were dissolved in DMSO (5 mL) under
vigorous stirring and maintained at room temperature for 1 h.
Then, the mixture solution was added to a dry solution of NH2–
PEG2000–NH2 (20 mg) in 5 mL DMSO through a dropping funnel
at a rate of 0.5 drop per s and maintained at room temperature
for 12 h. DMSO was removed by distillation at 60 C under
reduced pressure. The residual was dissolved in anhydrous
THF. Next, the resulting product was isolated by ltration to
remove the free FA, and then precipitated in anhydrous ethyl
ether to obtain the nal product NH2–PEG2000–FA.2.5. Preparation of ICG–GO–FA
GO (10 mL, 0.5 mg mL1) was rst mixed with NH2–PEG2000–FA
(5 mg) in an ultrasound bath for 10 min; aer the addition of
5 mg EDC and 3 mg NHS, the reaction mixture was kept stirring
for 24 h at room temperature. The surface decorated GO–FA was
obtained by dialysis in a 10 kDa dialysis bag against deionized
water. Next, GO–FA (GO concentration 0.5 mg mL1) was
incubated with ICG molecules (0.5 mg mL1) overnight to form
ICG–GO–FA. Unbound ICG molecules were removed by
ultraltration.2.6. Photothermal effect measurement
To study the photothermal effect induced by the NIR irradia-
tion, 1 mL aqueous solutions containing different materials
were irradiated by a NIR laser (808 nm, 1 W) for 10 min. The
temperatures of the solutions were monitored by a thermo-
couple microprobe (4¼ 0.5 mm) submerged in the solution in a
1 cm square cuvette. The probe was placed at such a position
that the direct irradiation of the laser on the probe was avoided.
The tip of the thermocouple was 5 mm above the bottom of
the cuvette.J. Mater. Chem. B, 2013, 1, 5762–5767 | 5763













































View Article Online2.7. In vitro photothermal therapy
To investigate the cancer cell killing efficiency of ICG–GO and
ICG–GO–FA under laser irradiation, Hela cells were incubated
with these composites at the same GO concentration (20 mgmL1)
under 37 C for 1 h. Aer washing with phosphate buffer for 3
times to remove the unbound composites, cells were exposed to
an NIR laser (808 nm) at a power density of 2 W cm2. At last, a
standard cell viability assay using MTT was conducted.Fig. 1 ICG–GO–FA preparation and characterization. (a) A schematic illustration
of ICG–GO–FA preparation and application. (b) An AFM image of GO (scale bar
represents 200 nm). (c) Absorption spectra of ICG–GO (blue) and GO (red).2.8. Photoacoustic imaging
To test the linearity of the photoacoustic signal as a function of
ICG–GO concentration, we used an agar-phantom with no
scattering or absorbing additives. ICG–GO at increasing weight
was mixed with warm liquid agar in multiples of 3 forming
ICG–GO solutions at 0.125, 0.25, 0.5, 1, 2 mg. Inclusions 2–3 mm
deep were made in the agar phantom and 100 mL of ICG–GO
solution was poured into the well. Upon solidication of the gel,
another layer of3 mm liquid agarose was poured on top of the
phantom. A complete photoacoustic image of the phantom was
acquired at 808 nm. 3D cylindrical ROIs at the size of the
inclusion were used to estimate the photoacoustic signal from
each well.
To compare the performance of plain ICG–GO and GO–FA to
ICG–GO–FA, we incubated increasing numbers of Hela cells
with ICG–GO, GO–FA and ICG–GO–FA respectively for a 1 h
period. Aer incubation, the cells were washed with cold saline
to remove unbound composites and then span down for 3 min
at 1500 rpm to remove excess liquid. We repeated this washing
process twice. The cells were then placed in an agarose
phantom at increasing numbers from 3  104 to 5  105 cells
per well. The agarose phantom was created in a similar way to
the other agarose phantoms mentioned above in this work (1%
ultrapure agarose, 99% DI water by weight). The wells in the
agarose phantom were made using a pipette tip. We mixed the
cell solution with warm agarose liquid and poured into the wells
of the agarose phantom. Aer 5–10 minutes the cell–agarose
solution solidied into the well and an additional liquid
agarose layer was deposited on the entire phantom to “seal” the
wells and protect the content of the wells. The phantom was
then positioned inside a water tank and a full 3D scan of the
phantom was taken using a photoacoustic instrument (Endra,
Nexus 128) at 808 nm wavelength. Quantitative analysis of the
photoacoustic signal from the phantom was done using the
OSIRIX soware by drawing 3D regions of interest around each
inclusion.3. Results and discussions
3.1. Preparation and characterization of ICG–GO and ICG–
GO–FA
Fig. 1a shows the illustration of ICG–GO–FA preparation and
application. GO was synthesized from graphite powder as
depicted in Section 2.2. Fig. 1b shows an AFM image of the
synthesized GO. The sizes of the GO sheets were 200 nm.
Tapping mode atomic force microscopy was used to determine
the thickness of the GO. The thickness of the GO sheets was5764 | J. Mater. Chem. B, 2013, 1, 5762–57671 nm, indicating that the synthesized GO was single-layered.
ICG molecules have four aromatic groups and four double
bonds in the carbon chain between two polycyclic parts which
are capable of forming strong p–p stacking interactions with
GO. Therefore, ICG–GO can be simply prepared through mixing
GO solution with ICG. The optical absorptions of GO and
ICG–GO were recorded. Fig. 1c indicates that ICG–GO showed
20 times higher optical absorption than GO alone at 808 nm.
ICG–GO was also characterized with uorescence spectroscopy.
In the characterization, the amount of GO was changed while
the concentration of ICG was xed. As shown in Fig. S1,† the
uorescence of ICG decreased as the concentration of GO
increased. Almost 100% quenching of uorescence was
observed when the weight of GO equaled that of ICG. This
observation indicates strong adsorption of ICG on GO. In order
to further investigate the stability of ICG–GO, the ICG–GO
complex was dispersed in cell culture media containing fetal
bovine serum in the dark for 3 hours. Aer that, the uores-
cence of ICG was measured to check the release of ICG from the
ICG–GO complex. Little uorescence recovery (less than 5%)
was observed (Fig. S2†), indicating that the ICG–GO complex is
very stable.
3.2. Comparison of the photothermal effect of different
materials
To verify the potential usage of ICG–GO in PTT, the photo-
thermal effect of different materials (GO, ICG, ICG–GO, and
RGO) has been compared. The results are shown in Fig. 2. An
ICG–GO solution (GO concentration 20 mgmL1) was exposed to
an 808 nm NIR laser at a power density of 1 W cm2 with GO
aqueous solution (20 mg mL1) as the control. From Fig. 2, a
small temperature increase of the GO solution could be
observed (curve D), indicating the poor photothermal property
of GO. We also tested the photothermal effect of ICG (curve C).
It can be observed that the photostability of ICG is poor. Aer
5 min of irradiation, the color of ICG solution changed from
green to yellow and the solution temperature began to decrease,
which indicated the degradation of ICG. A rapid temperature
increase of the ICG–GO solution was observed when exposed to
the laser (curve A). At the same time, the adsorption of ICG onto
GO can prevent the decomposition of ICG. For comparison, the
temperature of hydrazine hydrate-reduced graphene oxideThis journal is ª The Royal Society of Chemistry 2013
Fig. 2 Temperature change curves of (A) ICG–GO, (B) RGO, (C) ICG and (D) GO
solutions exposed to the 808 nm laser at a power density of 1 W cm2.
Fig. 3 Cytotoxicity of (A) control, (B) GO–FA, (C) ICG–GO–FA, (D) ICG–GO to
cancer cells and photothermal ablation of cancer cells based on (E) control, (F)
GO–FA, (G) ICG–GO–FA, (H) ICG–GO.













































View Article Online(RGO, 20 mg mL1) solution treated with the same irradiation
condition was also recorded (curve B). It can be seen that the
photothermal effect of ICG–GO is comparable to that of RGO
prepared by our group and that reported in the literature29
(Fig. S3†) and is better than that of ICG–SWNT.46 Aer laser
irradiation, the uorescence of ICG–GO solution was measured
immediately. No obvious uorescence recovery was observed
(Fig. S2†). This suggests that laser irradiation does not result in
the release of ICG from the ICG–GO complex. These results
demonstrated that ICG–GO exhibited an excellent photo-
thermal property and good photostability.Fig. 4 The photoacoustic signal produced by ICG–GO was observed to be
linearly dependent on the GO concentration.3.3. Cellular photothermal therapy
Motivated by the strong NIR absorbance and highly effective
photothermal heating of ICG–GO, we then carried out an in vitro
photothermal therapy study. In order to improve the cancer-
targeting, GO was modied with FA. Hela cells were incubated
in a solution of GO–FA, ICG–GO or ICG–GO–FA at the same GO
concentration (20 mg mL1) for 1 h. Before or aer 808 nm NIR
laser (2 W cm2, 10 min) irradiation, photothermal ablation of
Hela cells was conrmed by MTT experiments; the results are
shown in Fig. 3. Before irradiation, the incubation of Hela cells
with GO–FA, ICG–GO or ICG–GO–FA only resulted in a smaller
decrease of cell viabilities (Fig. 3B, C and D) than the control
(Fig. 3A), indicating that GO–FA, ICG–GO and ICG–GO–FA are
less toxic and highly biocompatible. As expected, the NIR irra-
diation alone did not inhibit cell viability (Fig. 3E), suggesting
that the irradiation of NIR light is relatively harmless. In
contrast, the viabilities of Hela cells that were irradiated with
NIR light aer incubation with ICG–GO–FA decreased to 8%
(Fig. 3G). FA, a well-known low molecular weight vitamin, is
targeted to FR that is overexpressed on a wide range of human
cancers such as Hela cells. It is found that without FA or ICG,
the therapy effect is greatly limited (Fig. 3F). These results
demonstrated successful targeting and photothermal killing of
the Hela cells using ICG–GO–FA. Therefore, we believe that
ICG–GO–FA is a promising agent for targeted photothermal
ablation of cancer cells in vivo.This journal is ª The Royal Society of Chemistry 20133.4. Cellular photoacoustic imaging
As is reported by many groups, materials with a photothermal
effect usually can be used as contrast agents for photoacoustic
imaging.47,48 We found that ICG–GO can also be used as a
contrast agent for photoacoustic imaging. We constructed a
non-absorbing and non-scattering agarose phantom with
inclusions of ICG–GO at increasing weight from 125 ng to 2 mg
in multiples of 3. As shown in Fig. 4, the photoacoustic signal of
ICG–GO increased with increase of GO weight. The photo-
acoustic signal produced by ICG–GO correlated highly with GO
weight (R ¼ 0.99), suggesting that ICG–GO is an excellent
candidate for contrast enhancement for PAT. Furthermore, cell
uptake studies revealed that ICG–GO–FA showed a good
contrast enhancement to Hela cells while ICG–GO and GO–FA
failed to show satisfactory contrast enhancement (Fig. 5). This
maybe due to the fact that ICG–GO is not able to target Hela
cells and GO–FA has a much lower NIR absorption than ICG–
GO–FA.J. Mater. Chem. B, 2013, 1, 5762–5767 | 5765
Fig. 5 Photoacoustic images of Hela cells using ICG–GO–FA, ICG–GO or GO–FA
as a contrast agent.













































View Article Online4. Conclusions
In summary, a novel ICG–GO–FA nanocomposite was prepared
and used for effective PTT therapy and PAT imaging of cancer
cells based on its excellent photothermal effect and photo-
acoustic effect. Through adsorption of ICG, ICG–GO showed
20 times higher optical absorption compared with GO alone at
808 nm. The prepared ICG–GO exhibits excellent photothermal
properties and photostability under NIR irradiation. Successful
targeting and photothermal killing of the targeted cells using
ICG–GO–FA was demonstrated. Moreover, the applications of
dye-enhanced GO as ultrahigh sensitive photoacoustic imaging
agents were also demonstrated. Given its cost-effectiveness,
easy fabrication and low cytotoxicity, ICG–GO–FA would be a
promising candidate for photothermal therapy and photo-
acoustic imaging of cancers in vivo.
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